As industries across the globe are beginning to implement GenAI more and more, what will work look like for humans in the future? We asked Pietro Casella, MD at EQT Group, who is leading AI acceleration within the group's portfolio companies. Hear predictions for the future of GenAi from our full panel of industry experts by watching our full on-demand webinar: https://okt.to/4a36tx #chatgpt #generativeai #privateequity
Gain.pro
Durfkapitaal en privévermogen
Amsterdam, North Holland 23.024 volgers
Find, understand and track companies that matter to you
Over ons
Gain.pro is on a mission to provide global private market visibility. Our industry-leading platform combines advanced AI tech with local-for-local research. It delivers the highest quality information on the companies that matter to you most. We serve 100% of MBB/Big-4 advisories, clients representing >$500bn of private equity capital and more than 70% of the top-20 global M&A houses. Examples include Blackstone, Goldman Sachs and McKinsey. We lead the market on customer satisfaction, as validated by external research (User Evidence survey 2023). Gain.pro has been named as one of Europe’s top 50 fastest growing businesses, operating globally with offices in Amsterdam, London, Frankfurt, Warsaw and Bangalore.
- Website
-
http://gain.pro
Externe link voor Gain.pro
- Branche
- Durfkapitaal en privévermogen
- Bedrijfsgrootte
- 201 - 500 medewerkers
- Hoofdkantoor
- Amsterdam, North Holland
- Type
- Particuliere onderneming
- Opgericht
- 2018
- Specialismen
- Private Equity, M&A, Deal Sourcing, Advanced Analytics, Artificial Intelligence, Origination en Investment Banking
Producten
Locaties
-
Primair
Wibautstraat 137 d
Amsterdam, North Holland 1091 GP, NL
-
80 Coleman Street
Moorgate, England EC2R 5BJ, GB
-
Mainzer Landstraße 178
Frankfurt, Hesse 60327, DE
-
39-41, Rue de la Chaussée d'Antin
Paris, Île-de-France 75009, FR
Medewerkers van Gain.pro
Updates
-
Did you know that the time-to-market for new low-volume precision parts usually ranges from 1-3 years? This week, we analysed 88 European precision parts manufacturing players and collected valuable insights on the key differences between supply chains for low-volume and high-volume manufacturing, the expanding role of incumbents in customers’ development processes and the importance of end market proximity for identified players. PE interest has been modest, with ~40% of identified assets being sponsor-backed. Key reasons to invest include margin improvements through novel production techniques, end-customers nearshoring critical parts from Asia to Europe and co-development opportunities. On the other hand, rising operational expenses in Europe, substantial required investments and increasing competition in end markets with low entry barriers are detractors for investors. Aalberts Investments, Accursia Capital GmbH, Active Capital Company, Amundi, Arkéa Capital, Auctus Industries, Avedon Capital Partners, BNP Paribas Développement, BPE Unternehmensbeteiligungen, Bpifrance, Caisse d’Epargne, The Carlyle Group, Crédit Agricole Régions Investissement (Carvest), Castik Capital, Equistone Partners Europe, Groupe Crédit Agricole, Mutares SE & Co. KGaA, One Equity Partners, Silver Investment Partners GmbH & Co. KG, Siparex and UI Investissement, amongst others, are currently invested in the European precision parts manufacturing market. Interested? Read our full report: https://lnkd.in/dCvv-M5x #precisionparts #precisionengineering #criticalparts #precisionmanufacturing #criticalcomponents
-
🇫🇷 Gain.pro is heading to Paris for IPEM - where private equity decision-makers come together for top tier business meetings and thought leadership. Meet Maxime Jacquot, Anastasia McLain and Fanny Restuccia at our booth to explore how our private market intelligence platform can revolutionize your deal sourcing workflow. ⛳ You can also try your hand at our putting green to win some exciting prizes. 👋 We can't wait to see you in France! Pre-book a meeting with our team 👉 https://okt.to/1WzUso 🗓️ When: September 9th - 11th, 2024 📍Where: Palais des Congrès, Paris, France #ipem #privateequity
-
-
Did you know that ~700k total knee replacements are performed annually in the US, with a ~99% success rate? This week, we analyzed 81 players in the US Implants market and collected valuable insights into how an aging population and unhealthy lifestyles are driving demand for implants, while technological advancements are enabling players to meet this demand by improving lead times and procedure accuracy. PE-led interest has been significant, with >50% of identified incumbents being sponsor-backed. Herein, favorable structural trends (e.g. aging US population), economic resilience and higher adoption backed by advancements in AI and 3D printing attract investors. However, declining insurance reimbursement rates, a shortage of surgeons, lengthy regulatory approval processes and reputational risks from product recalls serve as detractors to investors. Ally Bridge Group, Alumni Ventures, Arboretum Ventures, ARCH Venture Partners, B Capital, Cormorant Asset Management, LP, Creative Ventures, Deerfield Management, Dolby Family Ventres, Endeavour, EQT Group, Frazier Healthcare Partners, General Catalyst, Gilde Healthcare, Greenoaks, H.I.G. Capital, InterWest Partners, KdT Ventures, Khosla Ventures, Lightstone Ventures, Lumira Ventures, Morgenthaler, MVM Partners, New Enterprise Associates (NEA), Norwest Venture Partners, OrbiMed, Perceptive Advisors, Polaris Partners, RC Capital, Redmile Group, Revelation Partners, Sectoral Asset Management, Sofinnova Partners, SV Health Investors, Third Rock Ventures, U.S. Venture Partners and Viking Global Investors are currently invested in the US Implants market. Interested? Read our full report: https://lnkd.in/g766t8fT #origination #privateequity #fintech #finance #implants #cardiology #neurology #dental #orthopedics #aesthetics #medicalimplants #healthcare #medtech
-
In our latest report, we breakdown all 23 subsectors in Europe. Out of them, Energy stands out as one of the fastest growing. 📈 Learn all about this subsector, including insights into its growth, profitability, capital intensity, leverage and internationalization, in "The European PE Asset Handbook." Get your copy here 👉 https://okt.to/JL3Owx #privateequity #energy #industry
-
Next month, Gain.pro will be at PE Insights London, the premier event for GPs and LPs, where the biggest names in private equity come together to share their insights and learnings from being at the top of the PE Industry for years. Pre-book a meeting with Angeline Pagal, George Humphreys or Isaac Ainooson to receive a personalized demo of our platform and see how our unparalleled digital solution can take your deal sourcing to the next level. Reach out to our team 👉 https://okt.to/PIJpsQ 🗓️ When: September 4th, 2024 📍Where: The Waldorf Hilton, London, WC2B 4DD #privateequity #conference
-
-
Did you know that it takes an average of ~426 days for cancer treatments to be approved in the EU whereas it only takes ~244 days in the US? This week, we analysed 126 European cancer diagnosis and treatment players and collected valuable insights about novel cancer therapies and how partnerships with big pharmaceutical groups can help incumbents overcome R&D cycles with substantial upfront investments and a long time to commercialisation. Investor-led interest has been significant, with ~70% of identified assets being sponsor-backed. Herein, factors appealing to investors include the strong risk-return relationship, in which successful drugs can reap the vast majority of the benefits and provide a significant ROI. At the same time, costly and lengthy regulatory approval processes and high R&D expenditures with potentially no promise of success are key deterrents for investors. Novo Holdings, Bpifrance, Andera Partners, EQT Group, M Ventures , Sofinnova Partners, Pfizer, RA Capital Management, BioMedPartners, Seventure Partners, Kurma Partners, Boehringer Ingelheim, Forbion, Pontifax Venture Capital, Wellington Partners, Eurazeo, SV Health Investors, Gimv, Versant Ventures, The Invus Group, Gilde Healthcare, Inkef, KKR, BlackRock, Fidelity Investments, Ackermans & van Haaren, Omega Funds, Qatar Investment Authority, Syncona Limited , coparion, Brandon Capital, HealthCap, redalpine, HTGF | High-Tech Gründerfonds, JEITO and Oxford Science Enterprises are currently invested in the European cancer diagnosis and treatment market. Interested? Read our full report: https://lnkd.in/egVUaWKz #origination #privateequity #fintech #finance #cancer #oncology #cancerdrugs #immunotherapy #immunooncology #cancerdetection #diagnosis #cancerdiagnosis #diagnostics #targetedtherapy
-
North American vs. European investors: how do their portfolios compare? 🌍 When looking at investments across regions, North American investors typically allocate a greater portion of assets to the UK and Italy compared to their European counterparts. Conversely, they allocate fewer investments to the Nordics, Benelux and French regions where there is stiff competition from regional European investors. 🏭 By sector, North American investors overweight TMT, Financials and Energy & Materials while being underweight in Services, Consumer and Science & Health. Specifically, the localized nature of the Services and Healthcare sectors, smaller company sizes, localized regulatory regimes and often (cross-border) M&A value creation stories make it somewhat harder for North American investors to execute many deals in this sector. For more insights on how North American and European investor portfolios compare against one another, read our 2024 edition of “The Europe 250.” 👉 Read it here: https://okt.to/mUSC8L #privateequityinvestors #investorranking #theeurope250
-
Did you know ~95% of all customer interactions are expected to be Generative AI enabled by 2025? This week, we analyzed 85 US gen AI players and gathered insights on how increased cloud computing adoption and integration of AI in business analytics and customer experience are driving demand for gen AI. PE-led interest has been substantial, with >70% of identified incumbents being investor-backed. Herein, the large return potential from emergent winners, rapid advancements in technology and opportunities to consolidate through buy-and-build attract investors. Conversely, the evolving and uncertain regulatory landscape and supply chain concerns for critical hardware serve as drawbacks. Accel, Addition, Amplify, Andreessen Horowitz, Battery Ventures, Benchmark, Bessemer Venture Partners, BlackRock, Coatue, Compound Ventures Inc., Dawn Capital, Dragoneer Investment Group, Felicis, First Round Capital, FirstMark, Founders Fund, Greycroft, Greylock, GV (Google Ventures), ICONIQ Capital, Index Ventures, Insight Partners, Intel Capital, IQT (In-Q-Tel), Khosla Ventures, Lightspeed, Lux Capital, Madrona Venture Labs, Menlo Ventures, Morgan Stanley, New Enterprise Associates (NEA), Nexus Venture Partners, Norwest Venture Partners, Omidyar Network, Sequoia Capital, SoftBank Group Corp., Sound Ventures, SV Angel, Tiger Global Management and Y Combinator are currently invested in the US gen AI market. Interested? Read our full report: https://lnkd.in/gpk6V_jN #genAI #chatgpt #AI #artificialintelligence #generativeAI #LLM
-
According to our research, M&A boosts overall growth rates for both independently held and PE-backed companies. For independently held companies, those with >5 add-ons grow at a CAGR of 12% versus a CAGR of 6.5% per annum for those with no acquisitions. For majority PE-backed companies, those with >5 add-ons grow at a CAGR of 21.9%. In comparison, those with no acquisitions grow at just 6.7% per annum. So why do PE-backed companies grow faster through M&A compared to the independently held? We dive into all of this and more in our latest research report "Comparing Private Equity and Independently Held Companies." Read the full report here: https://okt.to/HCzjZM #privateequitybusiness #independentlyheld #investing
-
Vergelijkbare pagina’s
Door vacatures bladeren
Financiering
Laatste ronde
Niet bekend gemaaktUS$ 9.974.115,00